An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

Toshko Lissitchkov,1 Anna Klukowska,2 Evgeny Buevich,3 Irina Maltceva,3 Guenter Auerswald,4 Oleksandra Stasyshyn,5 Wilfried Seifert,6 Tobias Rogosch6 1Specialized Hospital for Active Treatment (SHAT), Sofia, Bulgaria; 2Department of Paediatrics, Haematology and Oncology of Warsaw Medical University,...

Full description

Bibliographic Details
Main Authors: Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, Seifert W, Rogosch T
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:Journal of Blood Medicine
Subjects:
von willebrand disease
hemostatic efficacy
safety
prophylaxis
on-demand
surgery
Online Access:https://www.dovepress.com/an-open-label-extension-study-to-assess-the-long-term-efficacy-and-saf-peer-reviewed-article-JBM

Internet

https://www.dovepress.com/an-open-label-extension-study-to-assess-the-long-term-efficacy-and-saf-peer-reviewed-article-JBM

Similar Items